<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012788</url>
  </required_header>
  <id_info>
    <org_study_id>H-18041764</org_study_id>
    <nct_id>NCT04012788</nct_id>
  </id_info>
  <brief_title>CDI Synbiotic Study</brief_title>
  <official_title>The Effectiveness of a Synbiotic Mixture (Inulin, Lactobacillus Rhamnosus (LGG®), Lactobacillus Acidophilus (LA-5®), Lactobacillus Paracasei, and Bifidobacterium Lactis (BB-12®)), on Decreasing Recurrence of Clostridium Difficile Associated Diarrhea- a , Randomized, Placebo-controlled Study With 4 Weeks Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment with a synbiotic mixture consisting of inulin
      Lactobacillus rhamnosus (LGG®), Lactobacillus acidophilus (LA-5®), Lactobacillus paracasei
      (L. casei 431®) and Bifidobacterium lactis (BB-12®) can reduce the number of C. difficile
      recurrences significantly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics have been tested for their efficacy in preventing infection with C. difficile
      after antibiotic exposure. Some of the most effective probiotics tested Lactobacillus
      rhamnosus (LGG®), Lactobacillus acidophilus (LA-5®), Lactobacillus paracasei (L. casei 431®)
      and Bifidobacterium lactis (BB-12®). However, most studies have focused on prevention of the
      first incidence of C. difficile infection rather than prevention of re-infection with C.
      difficile. Recurrence rates of C. difficile infection (CDI) among hospitalized patients are
      15-25% - either as relapses caused by the original organism or re-infection following
      treatment. The potential of probiotics in preventing re-infection is less studied in these
      patients. Further, prebiotics which are carbohydrates only metabolized by beneficial bacteria
      have gained much attention the recent years for their health benefits through stimulating
      growth of specific types of bacteria in the gut, and recent data from mouse studies show that
      the prebiotic inulin can eliminate C. difficile growth, but the use of prebiotics in relation
      to C. difficile elimination has yet to be proven in humans. The investigators hypothesize
      that treatment with a synbiotic mixture consisting of inulin Lactobacillus rhamnosus (LGG®),
      Lactobacillus acidophilus (LA-5®), Lactobacillus paracasei (L. casei 431®) and
      Bifidobacterium lactis (BB-12®) can reduce the number of C. difficile recurrences
      significantly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced recurrence of C. difficile-associated diarrhoea (CDAD) after 8 weeks</measure>
    <time_frame>1 year</time_frame>
    <description>telephone questionnaire with patient at end of trial as well as examination of each patient's medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxin A and B levels measured by qPCR</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>probiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo powder, 15 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic mixture</intervention_name>
    <description>A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)</description>
    <arm_group_label>probiotic arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Placebo powder</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with primary CDI

          -  Treatment with Vancomycin

          -  Subjects over 18 years of age

          -  Signed informed consent

        Exclusion Criteria:

          1. Chemotherapy within two months and an absolute neutrophil count of &lt; 1000
             neutrophiles/mm3

          2. Acute leukemia

          3. Serious immunodeficiency

          4. Pancreatitis

          5. Planned or recent intraabdominal operation within a time window of 14 days

          6. Terminal disease with expected survival time &lt; 3 month

          7. Probiotic consumption within two weeks prior enrollment

          8. Pregnant or lactating women

          9. A history of inflammatory or irritable bowel disease

         10. Colectomy and cirrhosis

         11. Septicemia

         12. Toxic megacolon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Petersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastrounit, Hvidovre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas M Petersen</last_name>
    <phone>004538626199</phone>
    <email>andreas.munk.petersen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria IC Rubin</last_name>
    <email>ingrid.maria.cecilia.rubin@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas M Petersen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Munk Petersen</investigator_full_name>
    <investigator_title>MD, Cosultant, PhD</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>prebiotics</keyword>
  <keyword>synbiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

